Nanozymes Targeting Redox Imbalance: A Novel Weapon for Immunomodulation and Organ Protection in Sepsis

Area of Science:

• Biomedical Engineering
• Critical Care Medicine
• Nanotechnology

Background:

• Sepsis presents a significant challenge in critical care, characterized by high mortality rates.
• A key pathological mechanism involves a vicious cycle of reactive oxygen and nitrogen species (RONS) burst and cytokine storms, leading to multiple organ dysfunction syndrome (MODS).
• Current therapeutic strategies often fall short in interrupting this detrimental cycle, contributing to poor patient outcomes.

Purpose of the Study:

• To review the critical role of redox imbalance in sepsis progression.
• To explore the therapeutic potential of nanozymes in targeting redox imbalance for sepsis treatment.
• To discuss the in vivo behavior and safety of nanozymes and their prospects for clinical application.

Main Methods:

• Literature review focusing on redox imbalance in sepsis.
• Analysis of nanozyme properties, including antioxidant capacity, stability, and cost-effectiveness.
• Examination of studies on nanozyme efficacy in scavenging RONS and modulating inflammatory pathways.
• Review of data on nanozyme metabolic distribution and biosafety.

Main Results:

• Nanozymes exhibit potent antioxidant capabilities, effectively scavenging diverse RONS.
• Nanozymes demonstrate the ability to inhibit hyperactivated inflammatory pathways, thereby disrupting the RONS-cytokine storm cycle.
• These properties position nanozymes as a promising therapeutic strategy for sepsis, offering immunomodulation and organ protection.

Conclusions:

• Redox imbalance is a central factor in sepsis pathogenesis.
• Nanozymes represent a transformative therapeutic approach for sepsis due to their ability to regulate redox balance.
• Further research into nanozyme in vivo behavior and clinical translation is warranted to develop innovative sepsis therapies targeting the RONS-inflammation axis.